Abstract
The amyloid-β(Aβ ) cascade hypothesis of Alzheimers disease (AD) has dominated research and subsequent therapeutic drug development for over two decades. Central to this hypothesis is the observation that Aβ is elevated in AD patients and that the disease is ultimately characterized by the central deposition of insoluble senile plaques. More recent evidence, however, suggests that the presence or absence of plaque is insufficient to fully account for the deleterious role of elevated Aβ in AD. Such studies support the basis for an alternate interpretation of the Aβ cascade hypothesis. Namely, that soluble oligomers of Aβ (i.e., ADDLs) accumulate and cause functional deficits prior to overt neuronal cell death or plaque deposition. Accordingly, the following review focuses on research describing the preparation and functional activity of ADDLs in vitro and in vivo. These studies provide the basis for an alternate, ADDL-based, view of the Aβ cascade hypothesis and accounts for the disconnect between plaque burden and cognitive deficits. Possible therapeutic approaches aimed at lowering ADDLs in AD patients are also considered.
Keywords: NMDA antagonist, amyloid precursor protein, long-term potentiation (LTP), NSAID, glycosaminoglycans
Current Topics in Medicinal Chemistry
Title: The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease
Volume: 6 Issue: 6
Author(s): Susan M. Catalano, Elizabeth C. Dodson, Darrell A. Henze, Joseph G. Joyce, Grant A. Krafft and Gene G. Kinney
Affiliation:
Keywords: NMDA antagonist, amyloid precursor protein, long-term potentiation (LTP), NSAID, glycosaminoglycans
Abstract: The amyloid-β(Aβ ) cascade hypothesis of Alzheimers disease (AD) has dominated research and subsequent therapeutic drug development for over two decades. Central to this hypothesis is the observation that Aβ is elevated in AD patients and that the disease is ultimately characterized by the central deposition of insoluble senile plaques. More recent evidence, however, suggests that the presence or absence of plaque is insufficient to fully account for the deleterious role of elevated Aβ in AD. Such studies support the basis for an alternate interpretation of the Aβ cascade hypothesis. Namely, that soluble oligomers of Aβ (i.e., ADDLs) accumulate and cause functional deficits prior to overt neuronal cell death or plaque deposition. Accordingly, the following review focuses on research describing the preparation and functional activity of ADDLs in vitro and in vivo. These studies provide the basis for an alternate, ADDL-based, view of the Aβ cascade hypothesis and accounts for the disconnect between plaque burden and cognitive deficits. Possible therapeutic approaches aimed at lowering ADDLs in AD patients are also considered.
Export Options
About this article
Cite this article as:
Catalano M. Susan, Dodson C. Elizabeth, Henze A. Darrell, Joyce G. Joseph, Krafft A. Grant and Kinney G. Gene, The Role of Amyloid-Beta Derived Diffusible Ligands (ADDLs) in Alzheimers Disease, Current Topics in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/156802606776743066
DOI https://dx.doi.org/10.2174/156802606776743066 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimer’s Disease Targeted Nano-Based Drug Delivery Systems
Current Drug Targets Brain Ageing, Cognition and Diet: A Review of the Emerging Roles of Food-Based Nootropics in Mitigating Age-related Memory Decline
Current Aging Science Magnetic Resonance Imaging of Iron in Parkinsons Disease
Current Medical Imaging Identification of Electrophysiological Changes in Alzheimer's Disease: A Microarray Based Transcriptomics and Molecular Pathway Analysis Study
CNS & Neurological Disorders - Drug Targets Defining the earliest pathological changes of Alzheimer’s disease
Current Alzheimer Research Editorial [Hot Topic: Cognition Therapeutics (Guest Editor: Miao-Kun Sun)]
Current Drug Targets - CNS & Neurological Disorders Subject Index To Volume 8
Protein & Peptide Letters β -Amyloid: A Disease Target or a Synaptic Regulator Affecting Age-Related Neurotransmitter Changes?
Current Pharmaceutical Design Stem Cell Function, Self-Renewal, Heterogeneity, and Regenerative Potential in Skeletal Muscle Stem Cells
Recent Patents on Regenerative Medicine Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Vitamins and Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Obstructive Sleep Apnea Syndrome and Upper Airway Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Indications for Surgery and Operative Techniques in Infective Endocarditis in the Present Day
Infectious Disorders - Drug Targets Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design A Molecular Bridge: Connecting Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Drug Targets in Alzheimers Disease (Executive Editors: G. Munch and G. Stuchbury)]
Current Pharmaceutical Design Possible Involvement of Muscarinic Receptors in Psychiatric Disorders: A Focus on Schizophrenia and Mood Disorders
Current Molecular Medicine O-GlcNAc Modification and the Tauopathies: Insights from Chemical Biology
Current Alzheimer Research Shear Stress-sensitive Carriers for Localized Drug Delivery
Current Pharmaceutical Design Dexmedetomidine Use in General Anaesthesia
Current Drug Targets